trending Market Intelligence /marketintelligence/en/news-insights/trending/3d7tdqx1KsezZCqzR6ZBcQ2 content esgSubNav
In This List

Quidel's antepartum diagnostic test gets US FDA clearance

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Quidel's antepartum diagnostic test gets US FDA clearance

The U.S. Food and Drug Administration granted 510(k) clearance to Quidel Corp.'s Solana GBS Assay test, which detects Group B streptococcus in women nearing childbirth.

The bacteria can cause infections leading to sepsis, pneumonia and meningitis in newborns. Deafness and developmental disabilities may also result from the transmission Group B streptococcus at delivery.